ArticleADMET & DMPK2025

Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns.

Alendra Chakramurty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.